ImmunoMet raised $0.84 million to advance Lixumistat, an FDA-designated orphan drug in clinical trials for the treatment of pancreatic cancer and glioblastoma multiforme, two rare and difficult-to-treat malignancies with significant unmet need.
ImmunoMet raised $0.84 million to advance Lixumistat, an FDA-designated orphan drug in clinical trials for the treatment of pancreatic cancer and glioblastoma multiforme, two rare and difficult-to-treat malignancies with significant unmet need.